BlackRock Spot Ethereum ETF Leads the Pack Seeing $118M Inflows
BlackRock’s iShares Ethereum Trust exchange-traded fund (ETF) saw $118 million in inflows on Tuesday, according to data shared by Fireside Investors.
Ethereum spot ETFs experienced a significant net inflow of $33.7 million on July 30, seeing the total inflows turn positive since launching. Fidelity’s Ethereum Fund (FETH) is the second favourite among investors garnering $16.4 million.
Source: Fireside Investors
The nine products made their debut on July 23 and are the first ETFs to invest in Ethereum directly.
Grayscale Ethereum product trading under the ticker “ETHE” continues to bleed seeing $120.3 million in outflows. Outflows mirror previous investor behaviour seen with the Bitcoin Grayscale Trust when spot ETFs launched in January.
BlackRock’s ETH ETF Tops Charts With Record Inflows
In the first week of trading BlackRock’s iShares Ethereum Trust ETF trading under the ticker symbol “ETHA” is in the top 15 inflows of ETFs launched this year, notes Nate Geraci, president of The ETF Store, an advisory firm.
Tough Start For ETH ETFs
Ethereum spot ETFs saw a total net outflow of $ 98.2 million on July 29 and continued to have net outflows for four consecutive days. This was marked by investor withdrawals from high-fee legacy products converted to ETFs.
It is early days for the new Ethereum products which could still gather momentum.
“We believe Ethereum ETFs will attract inflows roughly a third the size of Bitcoin ETFs in the long term, aligning with the relative market caps and trading volumes of the two cryptocurrencies. While Bitcoin’s market cap is approximately 3.3 times that of Ether, the inflows into Ethereum ETFs are expected to be anywhere around 30% to 50% of those into Bitcoin ETFs,” notes Jag Kooner, head of derivatives at Bitfinex.
Kooner also notes since the launch of the Ethereum ETFs, the market has seen significantly higher volatility. Ethereum has also seen a “muted price response” and this is exactly as expected following a sell-the-news event analogous to the Bitcoin ETF launch, which also saw the BTC price fall, post-launch in January.
Ethereum is trading around $3,206 down 0.2% during press time.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
U.S. non-farm payrolls surge by 165,000 in October, far exceeding expectations! Unemployment rate unexpectedly drops to 4.1%, December rate hike expectations intensify
In October, US non-farm payrolls increased by 165,000, which is 2.5 times the Wall Street median forecast of 65,000 and represents an exceptionally strong deviation of about 5 standard deviations, exceeding the upper limit of all institutional forecast ranges. The unemployment rate unexpectedly fell from 4.2% to 4.1%, while the market had expected it to remain unchanged; average hourly wages also accelerated year-on-year growth to 3.1%. Meanwhile, the previous two months' non-farm payrolls were revised upwards by a total of 84,000. Following the release of the data, the yield on 2-year US Treasury bonds rose by 7 basis points, and the pricing of the probability of a Fed rate hike in December climbed to 70%.
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion
The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.
Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight
Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.
Crypto prices
More
